We are international
Donate
special ASH update TEXT SIZE   
Controversies in MM Mgmt

REPORT FROM THE IMF- AND ICHE-SPONSORED
CONTROVERSIES IN MYELOMA MANAGEMENT
01.03.05

The IMF sponsored a Corporate Friday Symposium preceding the 46th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The CME-certified symposium entitled, “Controversies in Myeloma Management: Diagnosis, Initial Treatment, and the Relapsing Patient” was jointly sponsored by the IMF and the Institute for Continuing Healthcare Education, an ACCME-accredited provider of continuing medical education.

CONTROVERSIES IN MYELOMA MANAGEMENT: Introduction
Diagnosis, Initial Treatment and the Relapsing Patient

PRELIMINARY CASE EVALUATION: AN INTERACTIVE ASSESSMENT OF AUDIENCE TREATMENT OPTIONS
By Morie A. Gertz, MD

NEW APPROACHES TO MYELOMA STAGING AND FRONT-LINE TREATMENT SELECTION
By Brian G.M. Durie, MD

CURRENT U.S. EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
By Bart Barlogie, MD, PhD

CURRENT EUROPEAN EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
By Gareth J. Morgan, MD

EVALUATION OF THE PATIENT IN INITIAL RELAPSE AND SELECTION OF SECOND-LINE THERAPEUTIC OPTIONS
By James D. Cavenagh, MD

OVERVIEW OF KYPHOPLASTY IN THE MANAGEMENT OF SPINAL TUMORS
By Sigurd Berven, MD

PRELIMINARY CASE EVALUATION REVISITED
By Morie A. Gertz, MD


 related articles